Apatinib in treating patients with recurrent or metastatic nasopharyngeal carcinoma who had failed prior platinum-based chemotherapy

doi:10.21037/tcr-20-1773

	Apatinib in treating patients with recurrent or metastatic nasopharyngeal carcinoma who had failed prior platinum-based chemotherapy
	Tao, Chan-Juan 3; Zhang, Peng 2; Zhou, Ling 1; Hu, Qiao-Ying 3; Chen, Xiao-Zhong 3
刊名	TRANSLATIONAL CANCER RESEARCH
	2020-10-01
卷号	9
关键词	Apatinib nasopharyngeal carcinoma (NPC) recurrent or metastatic platinum-based chemotherapy toxicity
ISSN号	2218-676X
DOI	10.21037/tcr-20-1773
通讯作者	Chen, Xiao-Zhong(chenxiaozhongzjrt@163.com)
英文摘要	Background: Platinum-based chemotherapy is the standard first-line treatment for recurrent/metastatic nasopharyngeal carcinoma (NPC); however, there is no standard regimen for those who failed first-line treatment. This study aimed to evaluate the efficacy and safety of apatinib in treating patients with recurrent/metastatic NPC who failed prior platinum-based chemotherapy. Methods: Patients aged 18-65 years with recurrent/metastatic NPC were treated with apatinib at an initial dose of 500 mg once daily and continued until disease progression, patient withdrawal, or unacceptable toxic effects. The primary endpoints were clinical benefit rate (CBR) and toxicity Secondary endpoints included progression-free survival (PFS) and overall survival (OS). Results: Nineteen patients were enrolled in this study. At the final follow-up, the CBR was 52.6% (95% CI: 29.8-76.2%) in the intention-to-treat population. The median PFS and OS were 3.7 (95% CI: 0.6-6.8) months and 12.9 (95% CI: 9.3-16.5) months, respectively. The most common grade 3-4 adverse events (AEs) were hand-foot syndrome [3 (15.8%)], neutropenia [2 (10.5%)], proteinuria [2 (10.5%)], oral mucosal pain [2 (10.5%)], hypertension [1 (5.3%)], hyponatremia [1 (5.3%)], artery dissection [1 (5.3%)], and nasopharyngeal hemorrhage [1 (5.3%)]. A serious Al.'s was reported in one patient who died of nasopharyngeal hemorrhage. Treatment with apatinib did not significantly influence patient-reported quality-of-life, except for nausea/vomiting and pain (P<0.05). Conclusions: Apatinib achieved modest disease control with acceptable toxicity in recurrent/metastatic NPC patients pretreated with platinum-based chemotherapy.
资助项目	Medical Health Science and Technology Project of Zhejiang Provincial Health Commission[2020372435]
WOS关键词	PHASE-II ; CANCER ; TRIAL ; ERA
WOS研究方向	Oncology
语种	英语
出版者	AME PUBL CO
WOS记录号	WOS:000585306900052
资助机构	Medical Health Science and Technology Project of Zhejiang Provincial Health Commission
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/105247]
专题	中国科学院合肥物质科学研究院
通讯作者	Chen, Xiao-Zhong
作者单位	1.Guangdong Med Univ, Grad Sch, Zhanjiang, Peoples R China 2.Univ Chinese Acad Sci, Dept Med Oncol, Canc Hosp, Zhejiang Canc Hosp,Inst Canc & Basic Med IBMC,Chi, Hangzhou, Peoples R China 3.Univ Chinese Acad Sci, Dept Radiat Oncol, Canc Hosp, Zhejiang Canc Hosp,Inst Canc & Basic Med IBMC,Chi, Hangzhou, Peoples R China
推荐引用方式 GB/T 7714	Tao, Chan-Juan,Zhang, Peng,Zhou, Ling,et al. Apatinib in treating patients with recurrent or metastatic nasopharyngeal carcinoma who had failed prior platinum-based chemotherapy[J]. TRANSLATIONAL CANCER RESEARCH,2020,9.
APA	Tao, Chan-Juan,Zhang, Peng,Zhou, Ling,Hu, Qiao-Ying,&Chen, Xiao-Zhong.(2020).Apatinib in treating patients with recurrent or metastatic nasopharyngeal carcinoma who had failed prior platinum-based chemotherapy.TRANSLATIONAL CANCER RESEARCH,9.
MLA	Tao, Chan-Juan,et al."Apatinib in treating patients with recurrent or metastatic nasopharyngeal carcinoma who had failed prior platinum-based chemotherapy".TRANSLATIONAL CANCER RESEARCH 9(2020).